Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. (a foreign private issuer) covers the month of February 2021, specifically dated February 19, 2021. The filing announces the execution of a new Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to facilitate an "at the market" (ATM) offering of the Company's ordinary shares.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization to raise capital:
- Maximum Offering Size: Up to $50.0 million in aggregate offering price.
- Agent Commission: 3.0% of gross proceeds from sales.
- Registration: Shares will be issued under a shelf registration statement on Form F-3 (File No. 333-253300).
Material Changes
The material change reported is the replacement of a prior sales agreement. Evogene entered into this new agreement following the completion of all sales under a previous Controlled Equity Offering Sales Agreement dated January 14, 2021. This establishes a new framework for selling ordinary shares through the Agent via privately negotiated transactions or direct sales on trading markets.
Guidance, Outlook, and Risks
Outlook and Obligations: The Company is not obligated to sell any shares under this agreement. There is no assurance that any shares will be sold, nor is there any guarantee regarding the price, number of shares, or timing of potential sales.
Risks and Contingencies: The Sales Agreement may be terminated by either party as set forth in the document. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the effectiveness status of the Form F-3 Registration Statement (File No. 333-253300) to confirm the ability to issue shares.
- Monitor future filings for actual sales volumes and proceeds generated under the new $50.0 million ATM facility.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and price parameters.
- Check subsequent quarterly reports for the impact of the 3.0% commission on net proceeds if sales occur.